Discovery of a Highly Selective PLD2 Inhibitor (ML395): A New Probe with Improved Physiochemical Properties and Broad‐Spectrum Antiviral Activity against Influenza Strains. Issue 12 (10th September 2014)

• Record Type: Journal Article
• Authors: O'Reilly, Matthew C.; Oguin, Thomas H.; Scott, Sarah A.; Thomas, Paul G.; Locuson, Charles W.; Morrison, Ryan D.; Daniels, J. Scott; Brown, H. Alex; Lindsley, Craig W.
• Is Part Of: ChemMedChem. Volume 9:Issue 12(2014:Dec.)
• Page Start: 2633
• Page End: 2637
• Publication Date: 2014-09-10
• Subjects: Pharmaceutical chemistry -- Periodicals; 615.19005
• DOI: 10.1002/cmdc.201402333
• Languages: English
• ISSNs: 1860-7179

Abstract

<abstract abstract-type="main" xml:lang="en"> <title>Abstract</title> <p>Further chemical optimization of the halopemide‐derived family of dual phospholipase D1/2 (PLD1/2) inhibitors afforded ML395 (VU0468809), a potent, &gt;80‐fold PLD2 selective allosteric inhibitor (cellular PLD1, IC₅₀&gt;30 000 n<sc>M</sc>; cellular PLD2, IC₅₀=360 n<sc>M</sc>). Moreover, ML395 possesses an attractive in vitro DMPK profile, improved physiochemical properties, ancillary pharmacology (Eurofins Panel) cleaner than any other reported PLD inhibitor, and has been found to possess interesting activity as an antiviral agent in cellular assays against a range of influenza strains (H1, H3, H5 and H7).</p> </abstract>